SAR-439459
- Generic Name
- SAR-439459
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 7EFI23P78R
- Background
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT05231668
- Locations
- 🇺🇸
UCLA Health_Site Number: 8400006, Los Angeles, California, United States
🇺🇸Yale University - Site Number:8400007, New Haven, Connecticut, United States
🇺🇸Indiana University School of Medicine_Site Number: 8400002, Indianapolis, Indiana, United States
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇰🇷
Investigational Site Number : 4100002, Seoul, Korea, Republic of
🇺🇸University of Illinois at Chicago- Site Number : 8400007, Chicago, Illinois, United States
🇺🇸University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.